Key clinical point: Hu5F9-G4 plus rituximab was safe and produced durable complete responses in patients with relapsed or refractory non-Hodgkin lymphoma.
Major finding: Rates of overall and complete responses were 50% and 36%, respectively, with most responses ongoing at the time of data cutoff.
Study details: A phase 1b study of 22 patients, including 15 with diffuse large B-cell lymphoma and 7 with follicular lymphoma.
Disclosures: The study was supported by Forty Seven and the Leukemia & Lymphoma Society. Study authors reported disclosures related to Forty Seven, Bristol-Myers Squibb, Pharmacyclics, Seattle Genetics, and Roche/Genentech, among others.
Advani R et al. N Engl J Med. 2018;379:1711-21.
This Week's Must Reads
Caplacizumab approved for adults with aTTP , FDA news release: FDA approves first therapy for the treatment of adult patients with a rare blood clotting disorder
IVIG versus anti-D in pediatric ITP , Lioger B et al. J Pediatr. 2019; 204:225-33.
Promising treatment for heavy menstrual bleeding , O’Brien SH et al. J Pediatr Adol Gynec. 2019 Feb 4. doi: 10.1016/j.jpag.2019.01.009.
Beware of ICH in severe hemophilia cases , Zwagemaker AF et al. EAHAD 2019, Abstract OR08.
75 exposure days is the magic number in inhibitor risk , van den Berg HM et al. EAHAD 2019, Abstract OR05.
Must Reads in Aggressive Lymphomas
Researchers characterize new subtype of high-grade DLBCL, 3 articles from the Journal of Clinical Oncology
Patient perspectives on NHL treatment, Chircop D et al. Eur J Oncol Nurs. 2018 Aug;35:117-21
Corticosteroid use poses risk of febrile neutropenia, Chao CR et al. J Natl Compr Canc Netw. 2018;16(10):1201-8
5F9 plus rituximab looks durable in NHL, Advani R et al. N Engl J Med. 2018;379:1711-21
Age is an independent predictor of mortality after transplant, Kyriakou C et al. Biol Blood Marrow Transplant. 2018 Sep 13. doi: 10.1016/j.bbmt.2018.08.025